<DOC>
	<DOC>NCT00120705</DOC>
	<brief_summary>The purpose of this study is to assess the ability of darbepoetin alfa to maintain hemoglobin concentrations greater than or equal to 10 g/dL when administered every 3 weeks (Q3W).</brief_summary>
	<brief_title>Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects with nonmyeloid malignancies Anemia (screening hemoglobin concentration greater than or equal to 10.5 g/dL but less than or equal to 12.0 g/dL) related to cancer and chemotherapy At least 8 additional weeks of cyclic chemotherapy planned regardless of schedule Karnofsky Performance Status of greater than or equal to 50% Serum creatinine concentration less than or equal to 2.0 mg/dL Exclusion Criteria: Iron deficiency Red blood cell (RBC) transfusion within 4 weeks of screening Unstable cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>anemia</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>Amgen</keyword>
	<keyword>Non-myeloid Malignancies</keyword>
</DOC>